Pelthos Therapeutics Inc.

NYSE MKT:PTHS USA Biotechnology
Market Cap
$224.76K
Market Cap Rank
#39079 Global
#12720 in USA
Share Price
$23.85
Change (1 day)
-0.62%
52-Week Range
$16.19 - $37.42
All Time High
$37.42
Categories
Companies in USA Biotechnology
About

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Ther… Read more

Pelthos Therapeutics Inc. (PTHS) - Cash Flow Conversion Efficiency

Latest cash flow conversion efficiency as of September 2025: -0.262x

Based on the latest financial reports, Pelthos Therapeutics Inc. (PTHS) has a cash flow conversion efficiency ratio of -0.262x as of September 2025.

Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.26 Million) by net assets ($58.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Pelthos Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2021–2024)

This chart illustrates how Pelthos Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

Pelthos Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Pelthos Therapeutics Inc. ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Nordea Invest Basis 3 KL 1
CO:NDIB3KL1
 		N/A
ALLERTHAL-WERKE (ATW.SG)
STU:ATW
 		N/A
Alternative Investment Corporation
PINK:AIKO
 		0.018x
Newtek Business Services Corp. 5.50% Notes Due 2026
NASDAQ:NEWTZ
 		0.125x
Associated Banc-Corp 6.625% Fixed-Rate Reset Subordinated Notes due 2033
NYSE:ASBA
 		N/A
Brookfield Infrastructure Finance ULC
NYSE:BIPJ
 		N/A
Coop Opsparing Modig
CO:COIMOD
 		N/A
Star Minerals Ltd
AU:SMS
 		-0.110x

Annual Cash Flow Conversion Efficiency for Pelthos Therapeutics Inc. (2021–2024)

The table below shows the annual cash flow conversion efficiency of Pelthos Therapeutics Inc. from 2021 to 2024.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 $-2.71 Million $-5.79 Million 2.134x +1302.03%
2023-12-31 $-6.44 Million $-981.03K 0.152x -64.00%
2022-12-31 $-3.71 Million $-1.57 Million 0.423x -2.32%
2021-12-31 $-3.68 Million $-1.59 Million 0.433x --